<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Erythromycin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int169-erythromycin.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int169-erythromycin.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int169-erythromycin.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int127-antibacterials.htm">Antibacterials</a> &gt; <a href="bnf_int166-macrolides.htm">Macrolides</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int168-clarithromycin.htm" title="Previous: Clarithromycin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int164-methenamine.htm" title="Next: Methenamine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Erythromycin</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Erythromycin</strong> has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>alfentanil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when parenteral</span> <span>erythromycin</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>erythromycin</span> <span>given with</span> <span>amisulpride</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>erythromycin</span> <span>given with</span> <span>arsenic trioxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when parenteral</span> <span>erythromycin</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span> <span>erythromycin</span> <span>given with</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int556-bromocriptine.htm">Bromocriptine</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>bromocriptine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>buspirone</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int557-cabergoline.htm">Cabergoline</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>cabergoline</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly inhibits metabolism of</span> <span>calcium-channel blockers</span> <span>(increased risk of side-effects)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int940-cilostazol.htm">Cilostazol</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>cilostazol</span> <span>(consider reducing dose of <span>cilostazol</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>erythromycin</span> <span>increased by</span> <span>cimetidine</span> <span>(increased risk of toxicity, including deafness)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>clozapine</span> <span>(possible increased risk of convulsions)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly inhibits metabolism of</span> <span>corticosteroids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1172-dienogest.htm">Dienogest</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>dienogest</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>disopyramide</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td><p><span>in vitro studies suggest a possible interaction between </span> <span>erythromycin</span> <span>and</span> <span>docetaxel</span> <span>(consult <span>docetaxel</span> product literature)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int553-domperidone.htm">Domperidone</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>erythromycin</span> <span>given with</span> <span>domperidone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>dronedarone</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>(reduce dose of <span>eplerenone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int640-estradiol.htm">Estradiol</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>estradiol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>everolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span> <span>erythromycin</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>avoidance of </span> <span>erythromycin</span> <span>advised by manufacturer of</span> <span>fluconazole</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int915-galantamine.htm">Galantamine</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>galantamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>erythromycin</span> <span>given with</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td><p><span>avoidance of </span> <span>erythromycin</span> <span>advised by manufacturer of</span> <span>lercanidipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int309-loratadine.htm">Loratadine</a></td><td><p><span>manufacturer of loratadine advises </span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>loratadine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td><p><span></span> <span>erythromycin</span> <span>inhibits the metabolism of</span> <span>methylprednisolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>inhibits metabolism of</span> <span>midazolam</span> <span>(increased plasma concentration  with increased sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>inhibits metabolism of</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when parenteral</span> <span>erythromycin</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when parenteral</span> <span>erythromycin</span> <span>given with</span> <span>pentamidine isetionate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>erythromycin</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>pravastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>quetiapine</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span> <span>erythromycin</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly increased)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>erythromycin</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td><p><span></span> <span>erythromycin</span> <span>reduces plasma concentration of</span> <span>rosuvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1155-rupatadine.htm">Rupatadine</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>rupatadine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>erythromycin</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>sildenafil</span> <span>—reduce initial dose of <span>sildenafil</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>erythromycin</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span> <span>erythromycin</span> <span>given with</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when parenteral</span> <span>erythromycin</span> <span>given with</span> <span>sulpiride</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>tadalafil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span> <span>erythromycin</span> <span>given with</span> <span>telaprevir</span> <span>(increased risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span>(also <span>theophylline</span> may reduce absorption of oral<span>erythromycin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly increases plasma concentration of</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span> <span>erythromycin</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span></span> <span>erythromycin</span> <span>possibly inhibits metabolism of</span> <span>valproate</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when parenteral</span> <span>erythromycin</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td><p><span></span> <span>erythromycin</span> <span>increases plasma concentration of</span> <span>vardenafil</span> <span>(reduce dose of <span>vardenafil</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1002-vinblastine.htm">Vinblastine</a></td><td class="cAI"><p><span></span> <span>erythromycin</span> <span>increases toxicity of</span> <span>vinblastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int859-zafirlukast.htm">Zafirlukast</a></td><td><p><span></span> <span>erythromycin</span> <span>reduces plasma concentration of</span> <span>zafirlukast</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int426-zopiclone.htm">Zopiclone</a></td><td><p><span></span> <span>erythromycin</span> <span>inhibits the metabolism of</span> <span>zopiclone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int390-zuclopenthixol.htm">Zuclopenthixol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when parenteral</span> <span>erythromycin</span> <span>given with</span> <span>zuclopenthixol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Erythromycin</strong> belongs to <strong>Macrolides</strong> and will have the following interaction information:</p><div class="cG"><p><strong>Note:</strong> See also Telithromycin</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>macrolides</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int556-bromocriptine.htm">Bromocriptine</a></td><td><p><span></span> <span>macrolides</span> <span>possibly increase plasma concentration of</span> <span>bromocriptine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int557-cabergoline.htm">Cabergoline</a></td><td><p><span></span> <span>macrolides</span> <span>possibly increase plasma concentration of</span> <span>cabergoline</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>macrolides</span> <span>possibly inhibit metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>macrolides</span> <span>increase plasma concentration of</span> <span>digoxin</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span> <span>macrolides</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span> <span>macrolides</span> <span>given with</span> <span>ergotamine and methysergide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>macrolides</span> <span>possibly inhibit metabolism of</span> <span>mizolastine</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>avoidance of </span> <span>macrolides</span> <span>advised by manufacturer of</span> <span>reboxetine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Erythromycin</strong> belongs to <strong>Antibacterials</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1058-typhoid-vaccine-oral.htm">Typhoid Vaccine (oral)</a></td><td><p><span></span> <span>antibacterials</span> <span>inactivate</span> <span>oral typhoid vaccine</span> <span>—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="PHP8409-typhoid-vaccines.htm">section 14.4</a></span>  </p></td><td></td></tr></tbody></table></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int168-clarithromycin.htm">Previous: Clarithromycin</a> | <a class="top" href="bnf_int169-erythromycin.htm#">Top</a> | <a accesskey="]" href="bnf_int164-methenamine.htm">Next: Methenamine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>